Village Farms (VFF) Q1 2026 Earnings Transcript

Village Farms reported Q1 consolidated net sales of $50.2 million, up 27% year over year, with adjusted EBITDA rising 118% to $9.9 million and net income improving to $2.7 million from a $2.1 million loss. International medical export sales surged 171% year over year to nearly $15 million, while cannabis gross margin expanded to 43% and the company completed its $10 million share repurchase authorization. Cash flow from operations was negative $16.8 million due to a CAD 16.4 million tax payment, but management expects a return to positive cash flow in Q2 and through the rest of 2026.

Analysis

VFF is emerging as a rare cannabis operator with enough scale discipline to turn regulatory friction into pricing power. The key second-order effect is that EU GMP certification is increasingly acting like a moat, not just a quality label: as non-compliant supply gets squeezed, compliant inventory should capture both share and margin even if category prices soften. That makes the international book less cyclical than headline cannabis pricing implies, and it also raises the bar for new entrants, especially U.S.-based exporters who will need multiple regulatory approvals before they can match service reliability.

The near-term overhang is cash flow timing, not business quality. The tax-driven working capital outflow will likely keep skeptics focused on operating cash burn for another quarter or two, but that looks more like a balance-sheet event than a demand problem. The more important catalyst is capacity ramp: Delta 2 and Groningen are set up to convert current demand into volume growth in the back half of the year, which should create operating leverage because SG&A is already fixed around current levels.

The market may be underestimating how much of VFF’s value is tied to optionality in Germany and the Netherlands rather than Canadian branded cannabis. If Germany remains price-stable for compliant product while broader category pricing weakens, VFF’s gross margin can expand even without heroic market-share gains. The contrarian risk is that investors over-assign value to U.S. rescheduling optionality; if federal clarity drags or Texas stalls, the stock could rerate on execution alone, which is positive but probably slower than the current narrative implies.

Key Decisions for Investors

• Go long VFF on a 3-6 month horizon: the setup is a classic capacity-ramp / fixed-cost leverage trade, with upside skew if Q2-Q3 cash flow turns positive as guided.
• Use call spreads instead of outright equity for VFF (e.g., 6-9 month tenor) to capture the Delta 2 and Groningen inflection while limiting downside from regulatory slippage in the Netherlands.
• Pair trade: long VFF / short a U.S.-optionality-heavy cannabis name that needs federal reform to re-rate; the thesis is execution vs. policy beta over the next 2 quarters.
• If buying equity, stage entries into any post-earnings or post-capacity-delay pullback: the risk/reward improves if the market sells the stock on temporary cash-flow noise rather than on demand deterioration.
• Avoid chasing after U.S. rescheduling headlines; the cleaner trade is to own the operator already monetizing compliant international supply, not the names priced for hypothetical future market access.